MCVT Among Core Aggregate ETFs
End-of-day Nov 13, 2026 · 82 Core aggregate ETFs by YTD
Bridgebio Pharma, Inc. 1.75%, Due 03/01/2031 3.6%Merit Medical Systems, Inc. 3%, Due 02/01/2029 3.0%Mirion Technologies, Inc. 0.25%, Due 06/01/2030 3.0%Uber Technologies, Inc. 0.875%, Due 12/01/2028 3.0%
| Returns | Today | 1W | 1M | 3M | YTD | 1Y | 3Y | 5Y | Max |
|---|---|---|---|---|---|---|---|---|---|
| Total return | −0.5% | +0.6% | −0.3% | −6.9% | — | — | — | — | +7.1% |
| Peer average | −0.1% | −1.3% | 0.0% | −1.3% | −1.2% | −0.9% | +15.0% | +1.5% | — |
| S&P 500 · VOO | −0.4% | +2.6% | −2.3% | −2.1% | +11.5% | +11.6% | +79.3% | +72.7% | — |
$36 of every $1,000 in MCVT is Bridgebio
| # | |||||
|---|---|---|---|---|---|
| 1 | —Bridgebio Pharma, 1.75%, Due 03/01/2031 | 3.59% | $359.28 | 650K | $1.1M |
| 2 | —Merit Medical Systems, 3%, Due 02/01/2029 | 3.02% | $301.70 | 800K | $933K |
| 3 | —Mirion Technologies, 0.25%, Due 06/01/2030 | 3.01% | $300.52 | 900K | $929K |
| 4 | —Uber Technologies, 0.875%, Due 12/01/2028 | 2.96% | $296.23 | 800K | $916K |
| 5 | —Ormat Technologies, 2.5%, Due 07/15/2027 | 2.88% | $287.63 | 800K | $889K |
| 6 | —Etsy, 1%, Due 06/15/2030 | 2.82% | $282.13 | 700K | $872K |
| 7 | —Nova 0%, Due 09/15/2030 | 2.82% | $281.86 | 700K | $871K |
| 8 | —TransMedics Group, 1.5%, Due 06/01/2028 | 2.81% | $280.53 | 700K | $867K |
| 9 | —Bloom Energy 0%, Due 11/15/2030 | 2.79% | $279.47 | 650K | $864K |
| 10 | —Granite Construction, 3.25%, Due 06/15/2030 | 2.73% | $273.39 | 500K | $845K |
| 11 | —Dropbox, 0%, Due 03/01/2028 | 2.65% | $264.68 | 750K | $818K |
| 12 | —Revolution Medicines, 0.5%, Due 05/01/2033 | 2.64% | $264.19 | 700K | $817K |
| 13 | —HAT I, LLC / HAT II, LLC 3.75%, Due 08/15/2028 | 2.63% | $262.67 | 550K | $812K |
| 14 | —Tetra Tech, 2.25%, Due 08/15/2028 | 2.62% | $262.18 | 700K | $810K |
| 15 | —Haemonetics 2.5%, Due 06/01/2029 | 2.59% | $259.24 | 650K | $801K |
Not enough history yet: MCVT needs a year of prices.
Official documents are being connected from SEC EDGAR: […]. Read the issuer’s prospectus before investing.
Estimated yearly cost excludes trading costs and assumes constant assets.
| Ex-date | Paid | Per share |
|---|---|---|
| Sep 15, 2026 | Sep 21, 2026 | $0.0236 |
| Jun 15, 2026 | Jun 22, 2026 | $0.0075 |
of the $590B in 91 Core aggregate ETFs
| # | Ticker | Company | Weight ▼ |
|---|---|---|---|
| 1 | — | Bridgebio Pharma, 1.75%, Due 03/01/2031 | 3.59% |
| 2 | — | Merit Medical Systems, 3%, Due 02/01/2029 | 3.02% |
| 3 | — | Mirion Technologies, 0.25%, Due 06/01/2030 | 3.01% |
| 4 | — | Uber Technologies, 0.875%, Due 12/01/2028 | 2.96% |
| 5 | — | Ormat Technologies, 2.5%, Due 07/15/2027 | 2.88% |
| 6 | — | Etsy, 1%, Due 06/15/2030 | 2.82% |
| 7 | — | Nova 0%, Due 09/15/2030 | 2.82% |
| 8 | — | TransMedics Group, 1.5%, Due 06/01/2028 | 2.81% |
| 9 | — | Bloom Energy 0%, Due 11/15/2030 | 2.79% |
| 10 | — | Granite Construction, 3.25%, Due 06/15/2030 | 2.73% |